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Abstract
Background: Microsampling techniques have several 
advantages over traditional blood collection. Dried blood 
spot (DBS) sampling and blood collection with heparin-
ized capillaries are the standard techniques. Volumetric 
absorptive microsampling (VAMS) is a novel technique 
that collects a fixed volume of blood by applying an absor-
bent tip to a blood drop. In the present study we explored 
the feasibility of HbA1c monitoring with VAMS sampling at 
home and analysis in the laboratory.
Methods: Diabetic patients were enrolled in this study 
during consultation with the endocrinologist. A venous 
(adults) or capillary (children) sample was taken for 
immediate HbA1c analysis. DBS (n = 1) and dried VAMS 
(n = 2) were collected at home and sent to the laboratory. 
For 25 pediatric patients one VAMS was collected during 
consultation for immediate analysis (without drying), 
referred to as “wet VAMS”. HbA1c analyses were performed 
on a Tosoh HLC-723 G8 high-performance liquid chroma-
tography (HPLC) analyzer.
Results: The median time between sampling at home 
and analysis was 3 days. Results of HbA1c in dried VAMS 
showed a poor agreement with venous/capillary blood 
collected in hospital (concordance correlation coefficient 
CCC = 0.72). Similar observations were found with stand-
ard DBS. An excellent agreement was obtained between 
HbA1c results on wet VAMS (CCC = 0.996) and standard 
blood samples. Patients experienced VAMS and DBS as 
easy and convenient to use.
Conclusions: Utilizing equipment standard available in 
the clinical laboratory, the use of home-sampled dried 
VAMS and DBS is not a reliable tool for the monitoring 
of HbA1c. However, perfect agreement between HbA1c 
measured on wet VAMS and capillary microsamples was 
obtained.
Keywords: diabetes; dried blood spots; hemoglobin A1c; 
home-sampling; volumetric absorptive microsampling.
Introduction
Measurement of hemoglobin A1c (HbA1c) is essential for 
the diagnosis and monitoring of glycemic control both in 
type 1 and in type 2 diabetes mellitus [1]. The HbA1c result 
reflects the average glycemia of the last 100–120 days and 
is a predictive value for the development of micro- and 
macrovascular diabetes complications [2].
Diabetes mellitus has become a major public health 
problem causing significant morbidity and mortality. 
Especially type 2 has become a worldwide epidemic, both 
in adults and in children. The prevalence of diabetes mel-
litus is further increasing. In 2000 the global prevalence 
of diabetes was approximately 2.8% and for 2030 this is 
estimated to be 4.4%, an increase of total patients from 
171 million to 366 million [3]. This implies a growing need 
for HbA1c analyses, as it is the biomarker for diagnosis and 
follow-up of diabetes mellitus.
Microsampling refers to the collection of a small 
amount of blood (typically < 50 μL), most often via a fin-
gerprick. It is considered more patient-friendly, given its 
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minimal invasiveness. Also for HbA1c analysis, capillary 
microsampling (using precision capillaries) is increas-
ingly being applied as an alternative to traditional venous 
blood collection, especially in pediatric patients. Several 
studies have demonstrated a good agreement between 
venous and capillary HbA1c results in diabetic out-patients 
[4, 5], indicating that capillary and venous HbA1c results 
can be used interchangeably, although slight differences 
might be present in some populations [6].
Apart from liquid blood microsamples, also dried 
blood spots (DBSs) have been used for HbA1c analysis, with 
overall a good agreement between HbA1c results in liquid 
and dried blood samples [7]. It should be noted, however, 
that in the majority of these studies the DBS samples are 
artificial laboratory samples, generated by spotting eth-
ylenediaminetetraacetic acid (EDTA)-whole blood onto 
filter paper [8–15]. Only in a few studies a comparison was 
made between HbA1c in traditional venous samples and 
capillary DBS that were collected from patients at home 
[16–19]. While in DBS-based methods, the hematocrit, the 
volume of blood spotted on the DBS card, the spot homo-
geneity and capillary-venous differences can influence 
the derived results [20], these effects are unlikely to affect 
the HbA1c result, since the latter is a ratio (mmol/mol) [21]. 
DBS microsampling offers the advantage that it can be 
performed by non-phlebotomists, implying that a patient 
does not have to go to the hospital for a venepuncture but 
can perform the sampling at home [22]. Following drying, 
the DBS can be sent via standard postal services under 
ambient conditions to the analyzing laboratory prior to 
consultation. This allows the actual HbA1c value of the 
patient to be available at the time of consultation, allow-
ing insight into the most recent data. As a result, better 
adaptation of the treatment and glycemic control is to be 
expected. Volumetric absorptive microsampling (VAMS) is 
a novel microsampling technique advocated as an alterna-
tive to classical DBS sampling to eliminate the volumetric 
bias associated with the latter. An absorbent polymeric 
tip, attached to a handle, collects a fixed volume of blood 
(approximately 10 μL) by capillary action. Compared to 
DBS, the VAMS procedure is similar and even ensures 
further simplification of sampling and processing in the 
laboratory [23–25]. To the best of our knowledge, no study 
has already evaluated the use of VAMS for HbA1c analysis.
We explored the possibility of using VAMS as an alter-
native sampling procedure for HbA1c monitoring in a home 
sampling context, utilizing standard equipment for HbA1c 
analysis of routine liquid blood samples. To this end, we 
compared the HbA1c data from VAMS and DBS samples to 
those obtained following traditional liquid venous or capil-
lary blood sampling. We also investigated the possibility of 
using wet VAMS, which were collected in the hospital and 
immediately sent to and analyzed in the laboratory after 
collection, as an alternative sampling method in pediatric 
practice. Lastly, we also investigated the user friendliness 
of the different sampling techniques and which one would 
be preferred by patients to be used in future.
Materials and methods
Participants
This study was approved by the Ethics Committee of Ghent Univer-
sity Hospital. Diabetes patients (n = 100; 50 adults and 50 children) 
were recruited during consultation at the endocrinology depart-
ment of Ghent University Hospital. The participants gave written 
informed consent prior to participation. Samples from 86 patients 
were obtained. Only one exclusion criterion was applied: samples 
received 6  days after home sampling were excluded (one adult at 
10 days and one child at 12 days). All patients were diagnosed with 
type 1 or type 2 diabetes. Characteristics of the participants are sum-
marized in Table 1. There was one pediatric patient who only sent the 
VAMS samples back, without a DBS sample.
Specimen collection
This study took place from May to September 2015. For adults, a 
venous K2-EDTA-blood (Venosafe 4 mL VF-054SDK, Terumo, Leuven, 
Belgium) sample, and for children a capillary blood sample in a hep-
arinized capillary (Minicaps, Hirschmann, Neckartenzlingen, Ger-
many) was collected in the hospital for routine HbA1c measurement. 
Samples were sent at ambient temperature to the laboratory via a 
Table 1: Characteristics of the patient cohort.
All Adults Children
Patients, n 84 40 44
Age (years) median (IQR)a 16.5 (12.0–51.8) 54.0 (43.0–64.0) 12.0 (10.0–16.0)
Gender (males/females) 57 M/27 F 28 M/12 F 29 M/15 F
Hospital sampled HbA1cb (mmol/mol) median (IQR) 56 (49–66) 59 (49–67) 56 (50–63)
aIQR, interquartile range; bhospital sampled: for adults a venous K2-EDTA-blood sample and for the children a capillary blood sample in a 
heparinized capillary tube.
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pneumatic tube system and were analyzed upon arrival. These sam-
ples were considered as reference when comparing with the dried 
blood matrices, and are referred to as “hospital sampled blood”.
Following some explanation about the sampling, a home sam-
pling kit including a sampling brochure (see Supplemental data, 
 Figure  1) and a small survey was handed over to the participants. 
They were asked to spot a filter paper and fill two VAMS samples with 
capillary blood obtained by a finger prick. Pediatric patients were 
asked to use their own lancet (used for glycemia measurements). 
Adult participants received a disposable lancet (BD Microtainer Con-
tact-Activated Lancet: large flow, Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA), although they were also allowed to use 
their own lancet. The second VAMS was collected to check the repro-
ducibility of this novel sampling technique, allowing calculation of 
the imprecision of the VAMS sampling and the HbA1c analysis on 
these sampling systems. DBS were collected as described by Wilhelm 
et al. [26]. Blood drops were directly collected from the fingertip onto 
Whatman 903 Specimen Collection Paper (Whatman-GE Healthcare 
Life Sciences, Buckinghamshire, UK). The VAMS devices (Mitra, Phe-
nomenex, Torrance, CA, USA) were filled according to the company 
instructions. In brief, capillary blood was obtained by piercing a fin-
ger using a lancet. After wiping off the first blood drop, the tip of the 
VAMS sample was applied to the surface of the drop of blood. Upon 
turning completely red, the tip was held in place for an additional 2 s 
to ensure that it was completely filled. All samples were then dried 
at room temperature for at least 2 h, and one DBS and two VAMS 
were sent to the laboratory at ambient (non-controlled) temperature 
in a padded (bubble-wrap) envelope in the presence of a desiccant 
(Minipax absorbent packets, Sigma-Aldrich, St. Louis, MO, USA). We 
did not specifically inquire if the sampling at home was performed 
independently by the child. The HbA1c results from these dried blood 
matrices were compared with the reference.
The pediatric population was further split into two subgroups. 
Twenty-five patients were instructed to collect at home one DBS and 
two dried VAMS (the same procedure as for the adults). For the sec-
ond half of the pediatric patients, one VAMS was collected during 
consultation together with the heparinized capillary tube sample. 
This VAMS sample was capped with a shell (we used a pipet tip) to 
delay the drying process, and was immediately (within 1 h) analyzed 
in the laboratory. These samples are referred as “wet VAMS”. These 
patients were asked to fill one dried VAMS and one DBS at home.
HbA1c analysis
Both liquid blood and dried blood analyses were performed on a 
Tosoh HLC-723 G8 automated ion-exchange high-performance liquid 
chromatography (HPLC) analyzer (Tosoh Bioscience, Tokyo, Japan). 
All results were expressed in the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) units. HbA1c is separated 
from other hemoglobin components by the differences in ionic inter-
actions with the cation exchange group on the column. Within-run 
and between-run imprecision of the analyzer was ≤ 0.5%, measured 
with a low (30 mmol/mol) and high (84 mmol/mol) control. Impreci-
sion is expressed as the obtained coefficient of variation (CV).
Figure 1: Passing-Bablok regression analyses of HbA1c measurements in dried VAMS (A), DBS (B) and wet VAMS (C) relative to the capillary/
venous hospital blood samples.
The solid line represents the regression line with its 95% CIs indicated as dashed lines. Also the line of equality is shown as a dotted line. 
The slope and intercept are shown on the graphs with their 95% CIs in parentheses. Bland-Altman plots of HbA1c measurements in dried 
VAMS (D), DBS (E) and wet VAMS (F) relative to the capillary/venous hospital blood samples. The solid line represents the average difference 
with its 95% CI indicated as dotted lines. The dashed lines are the lower and upper limit of agreement (±1.96 SD). The gray area indicates 
the allowable error according to RCPA quality requirements (±4 mmol/mol). Note the differences in scale between D–E and F.
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The acceptance criteria for the HbA1c analyses on VAMS and DBS 
were based on the Royal College of Pathologists of Australasia (RCPA) 
quality requirements [27] and on unit-specific acceptance criteria 
defined by Weykamp et al. which are based on biological variation 
[28]. Throughout this article, the RCPA requirements were used as 
acceptance criteria (unless otherwise specified). These RCPA require-
ments state that if the target HbA1c result is ≤ 86 mmol/mol, an allow-
able error should be within ± 4 mmol/mol. If the target HbA1c result 
is > 86 mmol/mol, the measured value on VAMS and DBS should be 
within ± 5% limits of the target value [27].
Singlicate disks of 3 mm diameter were punched out of the DBS 
with a Harris Uni-Core Micropunch (Agilent Technologies, Santa 
Clara, CA, USA) and placed in 1 mL cups. Two hundred and fifty micro 
liter de-ionized water was added to the cup for extraction. The tips 
from the VAMS samples were separated from the body and placed in 
1 mL cups. Four hundred micro liter de-ionized water was added to 
the cup for extraction. The punches and the tips were both vortexed 
(Vortex V-1 Plus, Biosan, Riga, Latvia) for twice 30 s. The choice for 
twice 30 s was based upon preliminary experiments, where we com-
pared twice 30 s with 10 min vortexing (data not shown). The extracts 
were transferred to cups and analyzed on the Tosoh G8.
Data analysis
Data were analyzed using Excel software (Microsoft Corporation, 
Redmond, WA, USA) and MedCalc Statistical Software (MedCalc Soft-
ware bvba, Ostend, Belgium). Medians, interquartile ranges (IQRs) 
and CVs were calculated. The IQR is defined as the range between the 
25th and 75th percentile. The Spearman’s rank correlation coefficient 
ρ and the concordance correlation coefficient (CCC) were calculated. 
CCC quantifies the agreement between two measures of the same 
continuous variable. Following McBride GB, the CCC results were 
interpreted as: > 0.99, excellent agreement; 0.95–0.99 substantial 
agreement; 0.90–0.94, moderate agreement and < 0.90, poor agree-
ment [29]. Wilcoxon and Mann-Whitney statistical tests were used. 
p < 0.05 was used for statistical significance. Passing-Bablok regres-
sion analyses were performed and Bland-Altman plots were con-
structed to compare HbA1c results from both sampling techniques. 
Box and whisker plots were drawn to indicate the influence of the 
time between sampling and analysis on the HbA1c results.
Results
Prospective cohort study
For the evaluation of the HbA1c results, adults and chil-
dren were treated as a single cohort. The median time 
between sampling and analysis in the laboratory was 
3 days, ranging from 1 to 6 days (two samples of 10 and 
12 days were excluded).
A CV of 5.80% was obtained for the duplicate measure-
ments of dried VAMS samples. The 95% confidence inter-
val (CI) of the slope of the Passing-Bablok regression of the 
duplicate measurements contains 1 and the 95% CI of the 
intercept contains 0 (see Supplemental data, Figure 2).
Median HbA1c measured in dried VAMS was 56 mmol/
mol (n = 84; IQR 46–67 mmol/mol), in DBS 58 mmol/mol 
(n = 83; IQR 50–63 mmol/mol), and in hospital sampled 
blood (for adults a venous blood sample and for children 
a capillary blood sample collected in a heparinized capil-
lary) 56 mmol/mol (n = 84; IQR 49–66 mmol/mol). Results 
Figure 2: Box and whisker plots indicating the distribution and influence of time between sampling and analysis on HbA1c results in VAMS 
(A) or DBS (B).
The samples analyzed 0 days after sampling in figure A are the wet VAMS. The boxes represent medians and interquartile ranges, the 
minimum and maximum are indicated by the flags. The dotted lines represent the allowable errors according to RCPA quality requirements 
(± 4 mmol/mol). Outside and far outside values are shown as separate points. An outside value (indicated with an open circle) is defined as 
a value that is smaller/larger than the lower/upper quartile minus/plus 1.5 times the IQR. A far outside value (indicated with a closed circle) 
is defined as a value that is smaller/larger than the lower/upper quartile minus/plus 3 times the IQR.
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of HbA1c in dried VAMS and DBS were not significantly 
different from results of HbA1c obtained in the hospital 
acquired blood samples (Wilcoxon test p > 0.05). However, 
an unacceptably high number of samples did not meet the 
quality requirements, either using RCPA, IFCC or national 
glycohemoglobin standardization program (NGSP) accept-
ance criteria (Table 2). Agreement between HbA1c results 
in dried VAMS and in venous/capillary hospital samples 
was poor (ρ = 0.73, p < 0.0001; CCC = 0.72). Passing-Bablok 
regression curves and Bland-Altman difference plots for 
these analyses are shown in Figure 1A and D. A poor agree-
ment between DBS and capillary/venous hospital samples 
was obtained (ρ = 0.90, p < 0.0001; CCC = 0.88). Passing-
Bablok regression curves and Bland-Altman plots for the 
difference between HbA1c measured in DBS and venous/
capillary blood samples are shown in Figure 1B and E. The 
same conclusions could be drawn when adults and chil-
dren were treated as two single cohorts (data not shown).
Next, the influence of the time between sampling 
and analysis was investigated. The data were split in 
analyses performed 1–3 days or 4–6 days after sample col-
lection. For the samples analyzed after 1–3  days (n = 46) 
a higher agreement with the capillary/venous hospital 
samples was obtained (VAMS CCC = 0.74; DBS CCC = 0.94) 
than for those that were analyzed after 4–6 days (n = 31) 
(VAMS CCC = 0.65; DBS CCC = 0.76). The absolute differ-
ences between dried VAMS and capillary/venous HbA1c 
results analyzed after 1–3 days were not significantly dif-
ferent from those analyzed after 4–6 days (Mann-Whitney 
test p > 0.05). For the DBS, the absolute differences of the 
samples analyzed after 1–3  days were significantly dif-
ferent from the differences with the DBS analyzed after 
4–6 days (Mann-Whitney test p = 0.0001). This is graphi-
cally represented in Figure 2. Although samples analyzed 
within 3 days resulted in a high agreement, the results did 
not meet the RCPA criterion, as is evident from Figure 2.
Wet versus dried VAMS
The median HbA1c value measured in wet VAMS of the 
second pediatric cohort was 56 mmol/mol (n = 25; IQR 
49–62 mmol/mol). The median of the corresponding capil-
lary blood samples (collected in heparinized  capillaries in 
the hospital) was 56 mmol/mol (IQR 49–62 mmol/mol). All 
the 25 wet VAMS fulfilled the RCPA quality requirements. 
An excellent agreement between the wet VAMS and cap-
illary blood samples was obtained (ρ = 0.995, p < 0.0001; 
CCC = 0.996). Figure 1C and F shows the Passing-Bablok 
regression curve for the comparison of wet VAMS to capil-
lary blood samples and the  Bland-Altman difference plots.
User friendliness
Responses to questionnaires (see for detailed results Sup-
plemental data, Table 1) indicated that most participants 
experienced the VAMS and DBS sampling technique as 
very convenient to use. When asked for the preferred sam-
pling technique, VAMS clearly stood out, in both adults 
and children.
Discussion
Here, we present the results of a home sampling study 
for HbA1c monitoring. Starting point for this study was to 
evaluate whether, utilizing the equipment available in a 
standard clinical laboratory, dried blood samples col-
lected from VAMS and DBS can be applied for routine 
HbA1c monitoring. Although median HbA1c from VAMS 
and DBS did not differ significantly from venous/capil-
lary HbA1c, it is clear that in many instances the obtained 
HbA1c value deviated substantially from that obtained by 
whole blood sample analysis. This can at least partially 
be explained by the employed technique, in which limi-
tations are imposed regarding separation and integration 
of the different hemoglobin peaks on the chromatogram. 
Indeed, from our experiments it became evident that by 
aging of the dried samples the hemoglobin components 
are converted to oxidized and degraded hemoglobin [30]. 
The effect of this process on the HbA1c results appeared 
unpredictable, which had a negative impact on the analyt-
ical reliability of the measurements in these dried samples. 
Table 2: Numbers of dried VAMS and DBS samples meeting the acceptance criterion.
Applied acceptance criterion RCPA [27] Unit-specific [28]
NGSP units IFCC units
Total error criterion ± 4 mmol/mol ± 0.50% ± 5 mmol/mol
Number of dried VAMS meeting the criterion 33/84 (39%) 38/84 (45%) 35/84 (42%)
Number of DBS meeting the criterion 51/83 (61%) 64/83 (77%) 59/83 (71%)
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These variable effects on the HbA1c results become more 
pronounced as the time between collection and analysis 
of the dried sample is increasing. This was demonstrated 
by the higher agreement with the whole blood results in 
dried blood samples analyzed after 1–3  days than those 
analyzed after 4–6 days. This time effect on DBS analy-
ses was also observed by Mastronardi et  al. [18]. If the 
dried samples would be analyzed with the IFCC reference 
method [31], a better agreement and less deviating results 
are expected due to less interference of the formed hemo-
globin derivates. However, this would be at the expense of 
simplicity in the routine clinical laboratory. Therefore, we 
made a compromise and chose the routine HPLC method 
for the home sampling study because of the high through-
put capability and the existing integration in the routine 
laboratory. Indeed, to our opinion, amongst the require-
ments for a successful, straightforward implementation of 
an alternative sampling strategy as an extra clinical tool 
is the compatibility with current standard procedures and 
equipment.
A poor correlation and agreement between HbA1c 
results from dried VAMS and traditional sampling was 
observed. Also the Passing-Bablok regression showed a 
significant proportional difference. HbA1c results on dried 
VAMS deviated from the liquid blood results, with only 39% 
of the samples having an error lower than the 4 mmol/mol 
limit. The differences shown on the Bland-Altman plot for 
VAMS were highly variable and the limits of agreement 
were wider than those for DBS. DBS performed in general 
better than VAMS, although the agreement between HbA1c 
results in DBS and whole blood samples was also only 
moderate to poor (ρ = 0.90 and CCC = 0.88), with too many 
DBS that had a bias and did not meet the RCPA accept-
ance criterion. Passing-Bablok regression revealed a slope 
of 0.87. In contrast to Mastronardi et al. [18], it was in our 
case not possible to use a bias correction equation as the 
results demonstrate a large distribution in both directions. 
Interestingly, Fokkema et al. applying longer DBS elution 
times and utilizing immunoturbidimetry instead of auto-
mated ion-exchange HPLC, found a better concordance 
(Pearson correlation r = 0.987) between HbA1c measured 
in home sampled DBS and venous blood samples [19]. 
This might be owing to a higher robustness of immuno-
turbidimetry towards the hemoglobin conversions that 
take place upon drying. However, in Belgian laborato-
ries, HbA1c analysis via immunoturbidimetry is greatly 
outnumbered by automated ion-exchange HPLC, as the 
latter method has the advantage that it can be included in 
automated hematology systems. Moreover, ion-exchange 
HPLC is able to flag and visualize hemoglobin variants in 
the chromatograms.
In conclusion, when envisaging HbA1c measurements 
by standard automated ion-exchange HPLC and when 
taking into account the RCPA criterion, both DBS and 
VAMS failed. Notably, the results from dried VAMS were 
even considerably worse than those obtained from DBS, 
rendering the application of dried VAMS for routine home 
sampling for HbA1c measurements by standard clinical 
equipment, as applied here, clinically unacceptable. We 
hypothesize that the different constitution of VAMS (a 
hydrophilic polymer with wide pores) and filter paper (a 
multi-layered network of cotton fibers) may result in a 
better oxygenation – and hence more hemoglobin conver-
sion- in the former.
To our knowledge, this is the first study that evalu-
ated the feasibility of HbA1c measurements in VAMS in 
a real-life home sampling scenario. A large number of 
samples were obtained from both adult and pediatric dia-
betic patients, as both are the target population for meas-
urement of HbA1c in these dried blood matrices. Previous 
studies were limited to adult participants. All but one 
(Fokkema et al.) of the few published studies that made a 
comparison between HbA1c in traditional venous samples 
and capillary DBS collected from patients did not evaluate 
true patient-based sampling in a non-controlled environ-
ment (i.e. non-supervised sampling at home). As outlined 
above, the results from the Fokkema study cannot be fully 
compared with ours, as they used immunoturbidimetry, 
which is less commonly applied (at least in Belgium) [19]. 
In other studies, DBS were either collected by phleboto-
mists in a controlled examination center [16], by study 
examiners at the patient’s home [17] or by patients them-
selves in a controlled research setting [18]. In our study, the 
participants collected, after clear instructions, VAMS and 
DBS on their own at home. The samples were shipped to 
the laboratory via standard postal services. Hence, given 
our study design, a higher pre-analytical variation was 
expected. These aspects may explain why we obtained a 
somewhat lower correlation coefficient (ρ = 0.90) for the 
comparison between DBS and whole blood samples than 
another study (r = 0.96) that also used an ion-exchange 
HPLC technique to compare HbA1c in venous blood and 
capillary DBS [16]. Incompletely filled VAMS and small 
DBS were also analyzed and included in the study. We 
suspect that this has no influence on the results since 
HbA1c is a ratio measure.
For the dried VAMS technique, an imprecision of 
5.80% was obtained on duplicate measurements. This is 
higher than the desirable specification for imprecision 
(0.9%) based on biological variation [32]. However, when 
bearing in mind the deviating results of the dried VAMS 
and the unpredictability of aging on the HbA1c results 
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when analyzed via automated ion-exchange HPLC, VAMS 
can be considered as a reproducible sampling technique. 
Hence we hypothesize that the deviations are caused by 
the pre-analytical variability in the dried samples. In com-
parison, for the venous samples an imprecision of 0.40% 
and Bland-Altman ± 1.96 standard deviation (SD) limits of 
agreement of −0.59 and 0.53 were obtained on duplicate 
measurements (n = 30).
In this study we also evaluated the usability of the 
VAMS and DBS sampling and the donor’s preference for 
the various collection techniques. In general, VAMS and 
DBS sampling were found easy and convenient to use. 
Most of the participants preferred the VAMS sampling 
technique instead of the traditional blood sampling. 
This was even more striking in the pediatric population. 
We also showed that children are able to follow printed 
sample collection instructions.
Further research is necessary to evaluate how dried 
VAMS (and DBS) may be rendered more suitable to HbA1c 
measurement with the commonly applied ion-exchange 
HPLC routine clinical analyzers. A possibility is to pre-
immerse the tips of the VAMS in an anticoagulant (EDTA) 
or antioxidant, such as ascorbic acid, which can theoreti-
cally prevent the oxidation of hemoglobin. Although it is 
not known whether or not the blood truly coagulates on 
VAMS or DBS samples, in our preliminary study we used 
EDTA-anticoagulated venous blood for generating dried 
samples and those results deviated less than those from 
the patient cohort (data not shown). Interesting to note in 
this respect is that also a better correlation was observed 
in the studies that used the artificial laboratory samples 
(anticoagulated venous blood spotted on filter papers).
To evaluate the intrinsic potential of VAMS for HbA1c 
measurement, we also analyzed VAMS samples immedi-
ately (i.e. within an hour) after collection. This yielded 
an excellent agreement with HbA1c results in liquid cap-
illary blood samples (ρ = 0.995 and CCC = 0.996). Hence, 
this type of sampling can be used as an alternative for the 
rather inconvenient and cumbersome capillary microsa-
mpling technique used in pediatric practice. Moreover, 
the simplicity of VAMS might be combined with other 
approaches, allowing home sampling without the need 
for drying-thereby overcoming the issue of hemoglobin 
interconversions. Recently introduced systems for cap-
illary blood sampling include a capillary tube that after 
blood collection is transferred into a sample preparation 
vial containing a hemolyzing solution, which has a sta-
bilizing effect on HbA1c [33]. Combining VAMS collection 
with the stabilizing effect of such a solution may render 
home sampling of HbA1c and analysis with routine equip-
ment a feasible option in the near future.
Conclusions
VAMS is a novel sampling technique allowing simple 
 collection of capillary blood and processing in the labora-
tory. In this study, we evaluated the feasibility of VAMS as 
a home sampling tool for the monitoring of HbA1c when 
utilizing standard equipment (automated ion-exchange 
HPLC) for the analysis of routine liquid blood samples. 
Results of HbA1c measured in home sampled dried VAMS 
showed a poor agreement with the HbA1c measured in 
these liquid samples. Results were more deviating as the 
time between collection and analysis of the dried sample 
was increasing. Yet, the excellent agreement between 
HbA1c measured on wet VAMS and capillary microsam-
ples shows the intrinsic potential of VAMS. Hence, while 
in pediatric practice these wet VAMS can be used as an 
alternative for the more cumbersome glass capillaries, 
the dried VAMS approach, as applied here, needs further 
adaptation before becoming clinically acceptable. While 
both VAMS and DBS were experienced by the patients as 
convenient microsampling techniques, VAMS was by far 
the patients’ preferred technique.
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